ESP vs. EXORA Blocks for Analgesia in Laparoscopic Cholecystectomy
Launched by AYCAN KURTARANGİL DOĞAN · Mar 27, 2025
Trial Information
Current as of April 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two methods of pain relief for patients undergoing a laparoscopic cholecystectomy, which is a minimally invasive surgery to remove the gallbladder. The two methods being tested are called the Erector Spinae Plane (ESP) block and the External Oblique and Rectus Abdominis Plane (EXORA) block. The goal is to see which method helps control pain better after surgery and reduces the need for additional pain medications. Researchers believe that the EXORA block may provide better pain relief than the ESP block.
To participate in this study, individuals must be between 18 and 65 years old and scheduled for an elective laparoscopic cholecystectomy. They should be in good health according to specific criteria, meaning they should have no severe medical issues that could complicate the study. Participants will be randomly assigned to one of the two pain relief methods, and neither the patients nor the doctors will know which method they are receiving to ensure fairness in the results. Overall, participants can expect to help researchers understand which pain relief method is more effective, potentially improving comfort and recovery for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and 65 years
- • Undergoing elective laparoscopic cholecystectomy
- • Classified as American Society of Anesthesiologists (ASA) physical status I to III
- • Providing written informed consent
- Exclusion Criteria:
- • Known allergy or hypersensitivity to local anesthetics
- • Infection or skin lesions at the site of block application
- • Emergency surgical procedures
- • Refusal to participate in the study
- • Uncontrolled arterial hypertension
- • Uncontrolled diabetes mellitus
- • Mental retardation
- • Current use of antidepressant medications
- • Presence of metabolic disorders
- • Known bleeding diathesis
- • Morbid obesity (Body Mass Index \> 40 kg/m²)
About Aycan Kurtarangi̇l Doğan
Aycan Kurtarangi̇l Doğan is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, the organization collaborates with healthcare professionals and research institutions to conduct rigorous clinical trials. Aycan Kurtarangi̇l Doğan prioritizes ethical standards and regulatory compliance, ensuring that all studies contribute meaningful insights to the scientific community. Through a patient-centered approach, the sponsor aims to accelerate the development of effective therapies and improve healthcare solutions across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Aycan KURTARANGİL DOĞAN
Principal Investigator
Kütahya City Hospital
Ali Kaynak
Principal Investigator
Kütahya City Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported